Fertility concerns influence treatment decisions in younger patients with breast cancer
the ONA take:
Previous studies have shown that following a 5-year course of tamoxifen after breast cancer treatment can reduce recurrence by 47% and mortality by 26%.
In addition, more recent data suggests taking tamoxifen for 10 years may be even more beneficial. However, many patients with breast cancer, especially premenopausal women, decline the therapy or discontinue it in less than 5 years.
This study found that 13% of patients declined tamoxifen therapy and 16% stopped before the recommended 5 years of treatment were up.
Phone interviews conducted with 88 patients who did not initiate or discontinued tamoxifen revealed concerns about fertility and side effects were primary factors for these patients’ decision.
The researchers conclude these findings demonstrate a need to include appropriate counseling for patients who express concerns about future fertility at the outset as part of a multidisciplinary treatment plan.
They suggested that a dialog about fertility could identify more patients willing to complete the recommended course if they could delay or take a break from the therapy to allow for pregnancy.
A new international trial, called POSITIVE, being conducted by the International Breast Cancer Study Group, is looking at whether premenopausal women who take a hiatus to become pregnant then resume the therapy would have similar benefit as those who taken tamoxifen continuously for 5 years.
Previous studies have shown that following a 5-year course of tamoxifen after breast cancer treatment can reduce recurrence.
Sign Up for Free e-newsletters
- New Hypertension Threshold Guides Blood Pressure Management During Cancer Treatment
- Sexual Aids and Resources Not Readily Available at Cancer Centers
- 5-Year Overall Survival in Endometrial Cancer Not Improved With Chemoradiotherapy
- Factors Affecting Employment Participation in Early-stage Breast Cancer
- Gas Mixture Improves Efficacy of Breakthrough Cancer Pain Treatment
- Sitting With Silence in End-of-Life Cancer Care
- Obesity and Cancer Risk (Fact Sheet)
- Susceptibility Gene Mutations Common in Those With Pancreatic Cancer and History of Other Cancers
- Anticancer Properties of Omega-3 Fatty Acids: Plant-Based vs Marine-Based
- US Pharmacopeia Revises Chapter on Handling Hazardous Drugs
- Follow-Up After Treatment Lacking for Younger Cancer Survivors
- Adjuvant Vemurafenib Does Not Improve Disease-Free Survival in Melanoma
- Profile of Buparlisib and its Potential in the Treatment of Breast Cancer: Evidence to Date
- Exercise Before Lung Cancer Surgery Greatly Reduces Complications
- Hodgkin Lymphoma Treatment in EU vs US: Similarities Would Enable Worldwide Studies
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|